Laura Huppert, MD, discusses efficacy and safety outcomes from the phase 3 ASCENT-04 trial, which compared the combination of ...
Sacituzumab govitecan-hziy significantly improved progression free survival over standard chemotherapy in untreated mTNBC patients ineligible for immunotherapy. Topline data were announced from a ...
LAUSANNE, Switzerland & BARCELONA, Spain--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to ...
Pexidartinib is an oral small molecule that is believed to work by inhibiting colony stimulating factor-1 receptor (CSF1R). Sacituzumab govitecan is a Trop-2-directed antibody and topoisomerase ...
Patients with previously untreated, locally advanced, unresectable or metastatic triple-negative breast cancer who are not candidates for inhibitors of programmed cell death protein 1 (PD-1) or ...
Please provide your email address to receive an email when new articles are posted on . Researchers reported median OS of 14.5 months with sacituzumab govitecan vs. 11.2 months with physician’s ...
Please provide your email address to receive an email when new articles are posted on . First-line sacituzumab govitecan significantly improved PFS for metastatic triple-negative breast cancer subset ...
The US Food and Drug Administration (FDA) approved a new indication for sacituzumab govitecan (Trodelvy, Gilead Sciences) today for patients with unresectable, locally advanced or metastatic hormone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback